Trial · NCT04987489
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
NCT04987489, Phase 2, Completed, Forma Therapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease. Trials, record NCT04987489. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04987489
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
- NCT number
- NCT04987489
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 53 participants, actual
- Lead sponsor
- Forma Therapeutics, Inc.
- Conditions
- Sickle Cell Disease, Thalassemia
- Interventions
- Etavopivat tablets
- First posted
- 2021-08-03
- Last updated
- 2025-12-16
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohorts A: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Primary | Cohorts B: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Primary | Cohort C: Hemoglobin response rate at Week 12 (increase of ≥ 1.0 g/dL from baseline) | 12 weeks | Hemoglobin response rate at Week 12 (increase of ≥ 1.0 g/dL from baseline) |
| Secondary | Cohort A: Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Secondary | Cohort B: Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history | 12 weeks | Proportion of patients with ≥ 33% reduction in red blood cell transfusion over a continuous 12-week treatment period versus baseline red blood cell transfusion history |
| Secondary | Cohort A: Reduction in red blood cell transfusions over 12 weeks | 12 weeks | Reduction in red blood cell transfusions over 12 weeks |
| Secondary | Cohort A: Reduction in red blood cell transfusions over 24 weeks | 24 weeks | Reduction in red blood cell transfusions over 24 weeks |
| Secondary | Cohort A: Reduction in red blood cell transfusions over 48 weeks | 48 weeks | Reduction in red blood cell transfusions over 48 weeks |
| Secondary | Cohort B: Reduction in red blood cell transfusions over 12 weeks | 12 weeks | Reduction in red blood cell transfusions over 12 weeks |
| Secondary | Cohort B: Reduction in red blood cell transfusions over 24 weeks | 24 weeks | Reduction in red blood cell transfusions over 24 weeks |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04987489
GET https://conductscience.org/api/trials/v1/NCT04987489/registered